Te
Tempus AI
by Tempus AI
· Based in United States →
— Advancing precision medicine through the practical application of artificial intelligence in healthcare.
Overview
Tempus AI offers an AI-enabled precision medicine platform that integrates multimodal patient data to assist physicians and researchers. The platform aggregates clinical, molecular, and imaging data from various sources, including electronic health records (EHRs), laboratory information systems, and image management systems. This data is then structured and analyzed using AI to generate insights.
- What it does: Tempus AI provides tools for clinical decision support, clinical trial matching, and research. It utilizes generative AI and large language models (LLMs) to analyze unstructured data from patient records, such as clinical notes and pathology reports.
- Who it is for: The platform is designed for physicians, particularly in specialties like oncology and cardiology, and for the scientific and research community.
- How it fits a clinical or practice workflow: Tempus AI integrates with EHR systems, allowing physicians to access patient insights, reports, and clinical decision-support tools directly within their workflow. For example, Tempus One, a generative AI clinical assistant, can summarize patient history, assist during appointments by transcribing conversations and taking notes, and help with post-appointment tasks like documentation and treatment planning. The Tempus Hub serves as a physician’s interface for ordering tests and reviewing results. For researchers, platforms like Tempus Lens and Tempus Next Trials empower users to analyze de-identified patient data, build patient cohorts, and accelerate clinical trial enrollment.
- Notable capabilities: Key capabilities include AI-driven cohort building, automated record analysis, integration of clinical guidelines (e.g., ASCO guidelines), and an automated clinical update service that provides ongoing therapy monitoring and context-aware notifications. The platform also supports identifying patients for clinical trials by comparing patient data against eligibility criteria.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered ECG analysis
- Risk stratification for cardiac events
- Integration with clinical workflows
- Identification of subtle ECG biomarkers
- Support for precision medicine initiatives
Use Cases
- Enhanced diagnosis of cardiovascular diseases
- Early identification of at-risk patients
- Personalized treatment planning in cardiology
- Streamlining ECG interpretation for clinicians
Details
| Category | Clinical Decision Support & Reference, Lab & Diagnostics |
| Pricing | Unknown — unknown |
| Deployment | Cloud |
| Mobile App | Yes |
| API Available | Yes |
| Data Export | Yes |
| Languages | English |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status |
Unknown AI-estimated Tempus has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for several AI-enabled software devices. These include Tempus ECG-PH for detecting signs of pulmonary hypertension, Tempus ECG-MR for identifying undiagnosed mitral regurgitation, and Tempus ECG-AF for identifying patients at increased risk of atrial fibrillation/flutter. |
| GDPR | Yes AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine |
Social Proof
| Customers | unknown |
| Notable | Unknown |
What the Web Says
Tempus AI is a technology company that applies artificial intelligence and data analytics to precision medicine, primarily in oncology, but also expanding into cardiology and neuropsychiatry. They aim to build the world's largest library of molecular and clinical data to help physicians make data-driven decisions and personalize patient care. The company's business model involves genomic testing and diagnostic services, as well as licensing de-identified medical data to biopharma companies for research and clinical trial support.
Overall: MixedStrengths
- Leverages a vast and growing multimodal dataset (genomic, clinical, imaging) for AI analysis, which is difficult for competitors to replicate.
- Offers FDA-cleared diagnostics and has extensive peer-reviewed literature and partnerships with top pharmaceutical companies.
- Provides tools like Tempus One, a generative AI clinical assistant embedded in EHRs, to help clinicians query patient data in natural language.
- Enables physicians to optimize care by matching therapies and clinical trials to specific tumor mutations.
- Mission-driven culture with opportunities to work on meaningful healthcare challenges and cutting-edge AI applications.
- Strong revenue growth, expanding gross margins, and a robust contract pipeline, with expected profitability inflection.
Limitations
- Some employee reviews cite a toxic work environment, disorganization, poor management, and lack of work-life balance.
- Concerns about low pay, lack of 401k match, and limited opportunities for upward mobility for some roles.
- The business model relies on pooling massive amounts of sensitive genetic and medical records, raising data privacy and regulatory compliance risks.
- Critics argue that a significant portion of revenue comes from traditional diagnostic lab services rather than high-margin AI software.
- Real-world data from electronic medical records can be messy and incomplete, posing challenges for AI model training.
- The platform may be overscoped for non-oncology workflows, and dedicated tools might be better for specific non-oncology AI imaging.
Based on reviews from: Indeed.com, Built In, G2, AI Health Guide, IsolatedAlpha, Reddit, YouTube, MarketBeat, Capterra, The Silicon Review, AiAgents.computer, Dennis Gong, Zacks Investment Research Home, TradingView, BBAE Pro
Last updated: 2026-10-12
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Tempus AI
Press & Coverage
Tempus AI News Releases
Tempus Announces Multi-Year Collaboration with Moderna and Merck
Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy. Tempus will provide NGS sequencing and sample collection workflows to help bring personalized cancer vaccines to patients.
2026-10
Tempus AI News Releases
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Tempus AI, Inc. announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, where Tempus will showcase clinical research in cancer.
2026-10
Tempus AI News Releases
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus AI, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation.
2026-09
Tempus AI News Releases
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
Tempus announced an extension of its data license agreement with Recursion Pharmaceuticals and a new agreement under which Tempus will license Recursion's RNA Foundation Model.
2026-09
Tempus AI News Releases
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
Tempus AI, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension.
2026-08
Tempus AI News Releases
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
Tempus AI, Inc. announced study results published in Nature Medicine demonstrating that PRISM2, a multimodal slide-level pathology foundation model, can perform clinically important diagnostic tasks and be leveraged for various downstream applications.
2026-08
Tempus AI News Releases
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
Tempus AI, Inc. announced a landmark publication demonstrating the safe, real-world deployment of the Paige Prostate AI Suite within the UK National Health Service, highlighting enhanced diagnostic precision and accelerated turnaround times.
2026-07
Stocktwits
AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.
AI adoption is reshaping the medical device industry, with companies like Tempus AI (TEM) leveraging AI to advance precision medicine and drug development.
2026-10
Videos
Product demos, reviews, and walkthroughs for Tempus AI.
Loading videos...
Frequently Asked Questions
Tempus AI, particularly through its Tempus One and Tempus Hub platforms, is designed to integrate directly into Electronic Health Record (EHR) systems. This allows physicians to access patient reports, biomarker status, and AI-enabled insights without switching between multiple screens, aiming to streamline complex treatment decisions and reduce administrative tasks.
Tempus AI offers features such as summarizing patient history, treatment journey, and biomarker status for pre-appointment preparation, real-time transcription and intelligent note-taking during appointments, and post-appointment assistance for documentation, treatment planning, prior authorizations, and clinical trial matching. It also integrates clinical practice guidelines, such as ASCO's, to provide evidence-based recommendations.
Tempus AI states it is committed to patient privacy and is subject to HIPAA laws, employing rigorous de-identification processes for data used in research. However, there have been class-action lawsuits alleging that Tempus AI improperly used and shared genetic data obtained through an acquisition without proper patient consent, claiming genetic data cannot be truly de-identified.
While powerful, Tempus AI tools, such as Tempus ECG-AF, are intended to support clinical decision-making and should not be the sole basis for diagnosis or treatment. The results should be interpreted alongside other diagnostic information, including original ECG recordings, other tests, and the patient's clinical history. Additionally, the quality of AI algorithms is dependent on the quality of the data, and inconsistencies can weaken the algorithms.
Yes, several alternatives exist, including Corti, Glass Health, PathAI, Nuance DAX Copilot, and Suki AI. These alternatives offer various features like healthcare AI platforms with coding and speech-to-text, clinical intelligence with AI scribes, AI-powered pathology, and AI voice assistants. Some alternatives may offer free plans or different pricing structures compared to Tempus.
Specific pricing details for Tempus AI are not readily available publicly, as it often involves enterprise sales and custom pricing. However, Tempus generates revenue through testing services, data licensing, and subscription-based platforms. The company anticipates pricing changes for its core oncology assays, with FDA approval allowing for Advanced Diagnostic Laboratory Test (ADLT) pricing, which could increase annual average selling prices.
Suggest an Edit →
| Last Verified: 2026-10-12 | First Added: 2026-10-11
Investors who backed Tempus AI
Funded through the company that built this tool.
